BIOMAT Database Logo BIOMAT Database Logo

Systemic concentrations of salbutamol and HFA-134a after inhalation of salbutamol sulfate in a chlorofluorocarbon-free system. 1996

L I Harrison, and A Cline, and T M Wells, and J P Jacobson, and K M Cooper, and S F Chang, and J R Nelson, and B P Ekholm, and J Morganroth
Department of Drug Metabolism, 3M Pharmaceuticals, St. Paul, Minnesota 55144-1000, USA.

The objective of this study was to determine if salbutamol was absorbed from a new salbutamol sulfate chlorofluorocarbon (CFC)-free metered-dose inhaler (MDI). Measurement of HFA-134a, the CFC-free propellant, was included to provide proof of delivery of this MDI. Eight healthy men received two inhalations (90 micrograms salbutamol base equivalents per inhalation ex adapter) from the CFC-free inhaler (MDI A) in period 1 and from a reference CFC inhaler (MDI V) in period 2. Eight postdose samples were collected for the determination of salbutamol serum levels over a 4-h period. Salbutamol levels were not quantifiable in most samples. Four subjects given MDI A and two given MDI V had a few transient salbutamol levels, which occurred in the first hour after dosing, within a narrow range of 1-2 ng/ml and close to the lower limit of detection (1 ng/ml). No pharmacokinetic analyses were possible. Blood samples were also collected after MDI A for propellant quantitation. HFA-134a levels were seen in all subjects, verifying absorption. We conclude that the transient salbutamol serum levels can be attributed to the two-inhalation dose and not to either propellant system.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009330 Nebulizers and Vaporizers Devices that cause a liquid or solid to be converted into an aerosol (spray) or a vapor. It is used in drug administration by inhalation, humidification of ambient air, and in certain analytical instruments. Atomizers,Inhalation Devices,Inhalators,Inhalers,Vaporizers,Nebulizers,Vaporizers and Nebulizers,Atomizer,Device, Inhalation,Devices, Inhalation,Inhalation Device,Inhalator,Inhaler,Nebulizer,Vaporizer
D005617 Chlorofluorocarbons, Methane A group of methane-based halogenated hydrocarbons containing one or more fluorine and chlorine atoms. Fluorocarbon Aerosols,Fluorocarbon Propellants,Chlorofluoromethanes,Aerosols, Fluorocarbon,Methane Chlorofluorocarbons,Propellants, Fluorocarbon
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006845 Hydrocarbons, Fluorinated Inert liquid or gaseous halocarbon compounds in which FLUORINE replaces some or all HYDROGEN atoms. Fluorinated Hydrocarbons
D000280 Administration, Inhalation The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract. Drug Administration, Inhalation,Drug Administration, Respiratory,Drug Aerosol Therapy,Inhalation Drug Administration,Inhalation of Drugs,Respiratory Drug Administration,Aerosol Drug Therapy,Aerosol Therapy, Drug,Drug Therapy, Aerosol,Inhalation Administration,Administration, Inhalation Drug,Administration, Respiratory Drug,Therapy, Aerosol Drug,Therapy, Drug Aerosol
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000318 Adrenergic beta-Agonists Drugs that selectively bind to and activate beta-adrenergic receptors. Adrenergic beta-Receptor Agonists,beta-Adrenergic Agonists,beta-Adrenergic Receptor Agonists,Adrenergic beta-Agonist,Adrenergic beta-Receptor Agonist,Betamimetics,Receptor Agonists, beta-Adrenergic,Receptors Agonists, Adrenergic beta,beta-Adrenergic Agonist,beta-Adrenergic Receptor Agonist,Adrenergic beta Agonist,Adrenergic beta Agonists,Adrenergic beta Receptor Agonist,Adrenergic beta Receptor Agonists,Agonist, Adrenergic beta-Receptor,Agonist, beta-Adrenergic,Agonist, beta-Adrenergic Receptor,Agonists, Adrenergic beta-Receptor,Agonists, beta-Adrenergic,Agonists, beta-Adrenergic Receptor,Receptor Agonist, beta-Adrenergic,Receptor Agonists, beta Adrenergic,beta Adrenergic Agonist,beta Adrenergic Agonists,beta Adrenergic Receptor Agonist,beta Adrenergic Receptor Agonists,beta-Agonist, Adrenergic,beta-Agonists, Adrenergic,beta-Receptor Agonist, Adrenergic,beta-Receptor Agonists, Adrenergic
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

L I Harrison, and A Cline, and T M Wells, and J P Jacobson, and K M Cooper, and S F Chang, and J R Nelson, and B P Ekholm, and J Morganroth
HFA-134a (1,1,1,2-tetrafluoroethane); lack of oncogenicity in rodents after inhalation.
September 1995, Human & experimental toxicology,
L I Harrison, and A Cline, and T M Wells, and J P Jacobson, and K M Cooper, and S F Chang, and J R Nelson, and B P Ekholm, and J Morganroth
Switching patients with asthma from chlorofluorocarbon (CFC) albuterol to hydrofluoroalkane-134a (HFA) albuterol.
January 1999, The Journal of asthma : official journal of the Association for the Care of Asthma,
L I Harrison, and A Cline, and T M Wells, and J P Jacobson, and K M Cooper, and S F Chang, and J R Nelson, and B P Ekholm, and J Morganroth
Cumulative dose-response study of non-CFC propellant HFA 134a salbutamol sulfate metered-dose inhaler in patients with asthma.
March 1996, Chest,
L I Harrison, and A Cline, and T M Wells, and J P Jacobson, and K M Cooper, and S F Chang, and J R Nelson, and B P Ekholm, and J Morganroth
Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol.
March 1996, British journal of clinical pharmacology,
L I Harrison, and A Cline, and T M Wells, and J P Jacobson, and K M Cooper, and S F Chang, and J R Nelson, and B P Ekholm, and J Morganroth
Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol.
August 1996, British journal of clinical pharmacology,
L I Harrison, and A Cline, and T M Wells, and J P Jacobson, and K M Cooper, and S F Chang, and J R Nelson, and B P Ekholm, and J Morganroth
Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica.
January 2001, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine,
L I Harrison, and A Cline, and T M Wells, and J P Jacobson, and K M Cooper, and S F Chang, and J R Nelson, and B P Ekholm, and J Morganroth
Twenty-eight-day double-blind safety study of an HFA-134a inhalation aerosol system in healthy subjects.
June 1996, The Journal of pharmacy and pharmacology,
L I Harrison, and A Cline, and T M Wells, and J P Jacobson, and K M Cooper, and S F Chang, and J R Nelson, and B P Ekholm, and J Morganroth
Pharmacokinetics of HFA-134a: A Preliminary Report.
November 1996, American journal of therapeutics,
L I Harrison, and A Cline, and T M Wells, and J P Jacobson, and K M Cooper, and S F Chang, and J R Nelson, and B P Ekholm, and J Morganroth
Determination of the chlorofluorocarbon substitute 1,1,1,2-tetrafluoroethane (HFA-134a) in human and animal blood using gas chromatography with headspace analysis.
May 1995, Journal of chromatography. B, Biomedical applications,
L I Harrison, and A Cline, and T M Wells, and J P Jacobson, and K M Cooper, and S F Chang, and J R Nelson, and B P Ekholm, and J Morganroth
Clinical equivalence of a novel non-chlorofluorocarbon-containing salbutamol sulfate metered-dose inhaler and a conventional chlorofluorocarbon inhaler in patients with asthma.
July 1995, The Journal of allergy and clinical immunology,
Copied contents to your clipboard!